Drug Information

Drug General Information
Drug ID
D0SR4G
Former ID
DIB005924
Drug Name
ONT-093
Synonyms
MDR inhibitors, Ontogen; OC-144-093
Drug Type
Small molecular drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Discontinued in Phase 1 [546965]
Company
Ontogen Corp
Formula
C32H38N4O
Canonical SMILES
n1c(c([nH]c1c1ccc(/C=C/COCC)cc1)c1ccc(NC(C)C)cc1)c1ccc(<br />NC(C)C)cc1
CAS Number
CAS 216227-54-2
PubChem Compound ID
6450807
Target and Pathway
Target(s) Multidrug resistance protein 1 Target Info Inhibitor [527635]
KEGG Pathway ABC transporters
Bile secretion
MicroRNAs in cancer
NetPath Pathway IL2 Signaling Pathway
TCR Signaling Pathway
Pathway Interaction Database HIF-1-alpha transcription factor network
Reactome ABC-family proteins mediated transport
WikiPathways Nuclear Receptors in Lipid Metabolism and Toxicity
Abacavir transport and metabolism
Multi Drug Resistance Protein 1 (Glycoprotein 1) Regulation
Integrated Pancreatic Cancer Pathway
Allograft Rejection
Drug Induction of Bile Acid Pathway
Codeine and Morphine Metabolism
References
Ref 546965Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011621)
Ref 527635A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs. 2005 Aug;23(4):311-5.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.